3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
851
Lung Neoplasms
575
Small Cell Lung Carcinoma
164
Colorectal Neoplasms
130
Breast Neoplasms
104
Melanoma
100
Neoplasms
91
Ovarian Neoplasms
89
Neoplasm Metastasis
82
Pancreatic Neoplasms
74
Squamous Cell Carcinoma of Head and Neck
68
Stomach Neoplasms
59
Carcinoma, Renal Cell
54
Head and Neck Neoplasms
53
Esophageal Neoplasms
48
Triple Negative Breast Neoplasms
47
Endometrial Neoplasms
47
Prostatic Neoplasms
45
Uterine Cervical Neoplasms
41
Colonic Neoplasms
40
Urinary Bladder Neoplasms
39
Mesothelioma
38
Carcinoma, Hepatocellular
35
Mesothelioma, Malignant
34
Brain Neoplasms
30
Sarcoma
28
Carcinoma, Transitional Cell
28
Adenocarcinoma of Lung
28
Lung Diseases
24
Disease
24
Interventions
durvalumab
1
cemiplimab
1
atezolizumab
1
Pemetrexed
1
Nivolumab
1
Docetaxel
1
Cisplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vaccinia
×
Thoracic
×
90 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled